Document:

Exhibit 10.4

    

     

    

    PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT

    

    

    THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, dated as of [•], 2019 (as it may from time to time be amended, this “Agreement”), is entered into by and between SC Health Corporation, a Cayman Islands exempted company (the “Company”), and SC Health
      Holdings Limited, a Cayman Islands exempted company (the “Sponsor” or the “Purchaser”).

    

    

    WHEREAS, the Company intends to consummate an initial public offering of the Company’s units (the “Public Offering”), each unit consisting of one Class A Ordinary Share, par value $0.0001 per share, of the Company (an “Ordinary Share”), and one-half of one
      redeemable warrant as set forth in the Company’s registration statement on Form S-1, filed with the Securities and Exchange Commission (the “SEC”), File Number 333-[•] (the “Registration Statement”), under the Securities Act of 1933, as amended (the “Securities Act”). Each whole warrant entitles the holder
      to purchase one Ordinary Share at an exercise price of $11.50 per Ordinary Share. The Purchaser has agreed to purchase 5,000,000 warrants (or 5,450,000 in the aggregate if the over-allotment option in connection with the Public Offering is exercised
      in full) (the “Private Placement Warrants”), each Private Placement Warrant entitling the holder to purchase one Ordinary Share at an exercise price of $11.50 per Share.

    

    

    NOW THEREFORE, in consideration of the mutual promises contained in this Agreement and other good and valuable consideration, the
      receipt and sufficiency of which are hereby acknowledged, the parties to this Agreement hereby, intending legally to be bound, agree as follows:

    

    

    AGREEMENT

    

    

    Section 1.  Authorization, Purchase and Sale; Terms of the Private Placement
        Warrants.

    

    

    A.          Authorization of the
          Private Placement Warrants. The Company has duly authorized the issuance and sale of the Private Placement Warrants to the Purchaser.

    

    

    B.          Purchase and Sale of the
          Private Placement Warrants.

    

    

    (i)          On the date of the
        consummation of the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (the “Closing Date”), the Company shall issue and sell to
        the Purchaser, and the Purchaser shall purchase from the Company, 5,000,000 Private Placement Warrants at a price of $1.00 per warrant for an aggregate purchase price of $5,000,000 (the “Purchase
          Price”). The Purchaser shall pay the Purchase Price by wire transfer of immediately available funds, consisting of (i) $3,000,000 to the trust account, at a financial institution to be chosen by the Company, maintained by American Stock
        Transfer & Trust Company, acting as trustee, in accordance with the Company’s wiring instructions and (ii) $2,000,000 to the Company in accordance with the Company’s wiring instructions. On the Closing Date, upon the payment by the Purchaser of
        the Purchase Price, the Company, at its option, shall deliver a certificate evidencing the Private Placement Warrants duly registered in the Purchaser’s name to the Purchaser, or effect such delivery in book-entry form.

    

    

    (ii)       On the date of the
        consummation of the closing of the over-allotment option in connection with the Public Offering or on such earlier time and date as may be mutually agreed by the Purchaser and the Company (the “Over-allotment
          Closing Date”, and together with the Closing Date, the “Closing Dates”), the Company shall issue and sell to the Purchaser, and the Purchaser shall purchase from the Company, up
        to 450,000 Private Placement Warrants at a price of $1.00 per warrant for an aggregate purchase price of up to $450,000 (if the over-allotment option in connection with the Public Offering is exercised in full) (the “Over-allotment Purchase Price”). The Purchaser shall pay the Over-allotment Purchase Price by wire transfer of immediately available funds to the Company, to the trust account, at a financial institution to be chosen
        by the Company, maintained by American Stock Transfer & Trust Company, acting as trustee, in accordance with the Company’s wiring instructions to be provided separately in advance of the Closing Date. On the Over-allotment Closing Date, upon
        the payment by the Purchaser of the Over-allotment Purchase Price, the Company shall, at its option, deliver a certificate evidencing the Private Placement Warrants purchased by the Purchaser on such date duly registered in the Purchaser’s name to
        the Purchaser, or effect such delivery in book-entry form.

    

    

    
      
        

    

    

    

    

    

    C.          Terms of the Private
          Placement Warrants.

    

    

    (i)          Each Private Placement
        Warrant shall have the terms set forth in a Warrant Agreement to be entered into by the Company, the Sponsor and a warrant agent in connection with the Public Offering (a “Warrant Agreement”).

    

    

    (ii)        At the time of the
        closing of the Public Offering, the Company and the Purchaser shall enter into a registration rights agreement (the “Registration Rights Agreement”) pursuant to which the Company will
        grant certain registration rights to the Purchaser relating to the Private Placement Warrants and the Shares underlying the Private Placement Warrants.

    

    

    Section 2.  Representations and Warranties
        of the Company.  As a material inducement to the Purchaser to enter into this Agreement and purchase the Private Placement Warrants, the Company hereby represents and warrants to the Purchaser (which
      representations and warranties shall survive the Closing Dates) that:

    

    

    A.        Incorporation and
          Corporate Power. The Company is an exempted company duly incorporated, validly existing and in good standing under the laws of the Cayman Islands and is qualified to do business in every jurisdiction in which the failure to so qualify would
        reasonably be expected to have a material adverse effect on the financial condition, operating results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to carry out the transactions contemplated
        by this Agreement and the Warrant Agreement.

    

    

    B.          Authorization; No Breach.

    

    

    (i)          The execution, delivery
        and performance of this Agreement and the Private Placement Warrants have been duly authorized by the Company as of the Closing Dates. This Agreement constitutes the valid and binding obligation of the Company, enforceable in accordance with its
        terms. Upon issuance in accordance with, and payment pursuant to, the terms of the Warrant Agreement and this Agreement, the Private Placement Warrants will constitute valid and binding obligations of the Company, enforceable in accordance with
        their terms as of the Closing Dates.

    

    

    (ii)        The execution and
        delivery by the Company of this Agreement and the Private Placement Warrants, the issuance and sale of the Private Placement Warrants, the issuance of the Shares upon exercise of the Private Placement Warrants and the fulfillment of, and compliance
        with, the respective terms hereof and thereof by the Company, do not and will not as of the Closing Dates (a) conflict with or result in a breach of the terms, conditions or provisions of, (b) constitute a default under, (c) result in the creation
        of any lien, security interest, charge or encumbrance upon the Company’s equity or assets under, (d) result in a violation of, or (e) require any authorization, consent, approval, exemption or other action by or notice or declaration to, or filing
        with, any court or administrative or governmental body or agency pursuant to the Amended and Restated Memorandum and Articles of Association of the Company in effect on the date hereof or as may be amended prior to completion of the contemplated
        Public Offering, or any material law, statute, rule or regulation to which the Company is subject, or any agreement, order, judgment or decree to which the Company is subject, except for any filings required after the date hereof under federal or
        state securities laws.

    

    

    
      
        

    

    

    

    

    

    C.         Title to Securities.
        Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, and upon registration in the Company’s register of members, the Shares issuable upon exercise of the Private Placement Warrants will be duly and
        validly issued, fully paid and nonassessable. Upon issuance in accordance with, and payment pursuant to, the terms hereof and the Warrant Agreement, and upon registration in the Company’s register of members, the Purchaser will have good title to
        the Private Placement Warrants and the Shares issuable upon exercise of such Private Placement Warrants, free and clear of all liens, claims and encumbrances of any kind, other than (i) transfer restrictions hereunder and under the other agreements
        contemplated hereby, (ii) transfer restrictions under federal and state securities laws, and (iii) liens, claims or encumbrances imposed due to the actions of the Purchaser.

    

    

    D.         Governmental Consents.
        No permit, consent, approval or authorization of, or declaration to or filing with, any governmental authority is required in connection with the execution, delivery and performance by the Company of this Agreement or the consummation by the
        Company of any other transactions contemplated hereby.

    

    

    Section 3.  Representations and Warranties
        of the Purchaser. As a material inducement to the Company to enter into this Agreement and issue and sell the Private Placement Warrants to the Purchaser, the Purchaser hereby represents and warrants
      to the Company (which representations and warranties shall survive each Closing Date) that:

    

    

    A.          Organization and
          Requisite Authority. The Purchaser possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.

    

    

    B.          Authorization; No Breach.

    

    

    (i)         This Agreement
        constitutes a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, subject to bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and other laws of general applicability relating to or
        affecting creditors’ rights and to general equitable principles (whether considered in a proceeding in equity or law).

    

    

    (ii)        The execution and
        delivery by the Purchaser of this Agreement and the fulfillment of and compliance with the terms hereof by the Purchaser does not and shall not as of each Closing Date conflict with or result in a breach by the Purchaser of the terms, conditions or
        provisions of any agreement, instrument, order, judgment or decree to which the Purchaser is subject.

    

    

    C.          Investment
          Representations.

    

    

    (i)         The Purchaser is
        acquiring the Private Placement Warrants and, upon exercise of the Private Placement Warrants, the Shares issuable upon such exercise (collectively, the “Securities”), for the Purchaser’s
        own account, for investment purposes only and not with a view towards, or for resale in connection with, any public sale or distribution thereof.

    

    

    (ii)          The Purchaser
        understands that the Securities are being offered and will be sold to it in reliance on specific exemptions from the registration requirements of the United States federal and state securities laws and that the Company is relying upon the truth and
        accuracy of, and the Purchaser’s compliance with, the representations and warranties of the Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of the Purchaser to acquire such Securities.

    

    

    
      
        

    

    

    

    

    

    (iii)       The Purchaser did not
        decide to enter into this Agreement as a result of any general solicitation or general advertising within the meaning of Rule 502(c) under the Securities Act.

    

    

    (iv)       The Purchaser understands
        that no United States federal or state agency or any other government or governmental agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment in the Securities by the
        Purchaser nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

    

    

    (v)         The Purchaser understands
        that: (a) the Securities have not been and are not being registered under the Securities Act or any state securities laws, and may not be offered for sale, sold, assigned or transferred unless (1) subsequently registered thereunder or (2) sold in
        reliance on an exemption therefrom; and (b) except as specifically set forth in the Registration Rights Agreement, neither the Company nor any other person is under any obligation to register the Securities under the Securities Act or any state
        securities laws or to comply with the terms and conditions of any exemption thereunder. While the Purchaser understands that Rule 144 is not available for the resale of securities initially issued by shell companies (other than business combination
        related shell companies) or issuers that have been at any time previously a shell company, the Purchaser understands that Rule 144 includes an exception to this prohibition if the following conditions are met: (i) the issuer of the securities that
        was formerly a shell company has ceased to be a shell company; (ii) the issuer of the securities is subject to the reporting requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); (iii) the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was
        required to file such reports and materials), other than Form 8-K reports; and (iv) at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a
        shell company.

    

    

    (vi)        The Purchaser has such
        knowledge and experience in financial and business matters, knows of the high degree of risk associated with investments in the securities of companies in the development stage such as the Company, is capable of evaluating the merits and risks of
        an investment in the Securities and is able to bear the economic risk of an investment in the Securities in the amount contemplated hereunder for an indefinite period of time. The Purchaser has adequate means of providing for its current financial
        needs and contingencies and will have no current or anticipated future needs for liquidity which would be jeopardized by the investment in the Securities. The Purchaser can afford a complete loss of its investment in the Securities.

    

    

    Section 4.  Conditions of the Purchaser’s
        Obligations. The obligation of the Purchaser to purchase and pay for the Private Placement Warrants is subject to the fulfillment, on or before each Closing Date, of each of the following conditions:

    

    

    A.          Representations and
          Warranties. The representations and warranties of the Company contained in Section 2 shall be true and correct at and as of such Closing Date as though then made.

    

    

    B.          Performance. The
        Company shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before such Closing Date.

    

    

    
      
        

    

    

    

    

    

    C.          No Injunction. No
        litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory
        organization having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant Agreement.

    

    

    D.         Warrant Agreement.
        The Company shall have entered into the Warrant Agreement on terms satisfactory to the Purchaser.

    

    

    Section 5.  Conditions of the Company’s
        Obligations. The obligations of the Company to the Purchaser under this Agreement are subject to the fulfillment, on or before each Closing Date, of each of the following conditions:

    

    

    A.          Representations and
          Warranties. The representations and warranties of the Purchaser contained in Section 3 shall be true and correct at and as of such Closing Date as though then made.

    

    

    B.          Performance. The
        Purchaser shall have performed and complied with all agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Purchaser on or before such Closing Date.

    

    

    C.         Corporate Consents.
        The Company shall have obtained the consent of its Board of Directors authorizing the execution, delivery and performance of this Agreement and the Warrant Agreement and the issuance and sale of the Private Placement Warrants hereunder.

    

    

    D.         No Injunction.
        No litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory
        organization having authority over the matters contemplated hereby, which prohibits the consummation of any of the transactions contemplated by this Agreement or the Warrant Agreement.

    

    

    E.          Warrant Agreement.
        The Company shall have entered into the Warrant Agreement on terms satisfactory to the Company.

    

    

    Section 6.  Termination. This Agreement may be terminated at any time after December 31, 2019 upon the election by either the Company or the Purchaser upon written notice to the other party if the closing of the Public Offering does not
      occur prior to such date.

    

    

    Section 7.  Survival of Representations and
        Warranties. All of the representations and warranties contained herein shall survive each Closing Date.

    

    

    Section 8.  Definitions. Terms used but not otherwise defined in this Agreement shall have the meaning assigned to such terms in the Registration Statement.

    

    

    Section 9.  Miscellaneous.

    

    

    A.          Successors and Assigns.
        Except as otherwise expressly provided herein, all covenants and agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors of the parties hereto whether so
        expressed or not. Notwithstanding the foregoing or anything to the contrary herein, the parties may not assign this Agreement, other than assignments by the Purchaser to affiliates thereof (including, without limitation, one or more of its
        members).

    

    

    
      
        

    

    

    

    

    

    B.          Severability.
        Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be prohibited by or invalid under applicable law, such
        provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement.

    

    

    C.          Counterparts. This
        Agreement may be executed simultaneously in two or more counterparts, none of which need contain the signatures of more than one party, but all such counterparts taken together shall constitute one and the same agreement.

    

    

    D.          Descriptive Headings;
          Interpretation. The descriptive headings of this Agreement are inserted for convenience only and do not constitute a substantive part of this Agreement. The use of the word “including” in this Agreement shall be by way of example rather than
        by limitation.

    

    

    E.          Governing Law. This
        Agreement shall be deemed to be a contract made under the laws of the State of New York and for all purposes shall be construed in accordance with the internal laws of the State of New York.

    

    

    F.          Amendments. This
        Agreement may not be amended, modified or waived as to any particular provision, except by a written instrument executed by all parties hereto.

    

    

    
      

      

      [Signature Page Follows]

      

      

      
        
          

      

      

      

      

      

      IN WITNESS WHEREOF, the parties hereto have executed this Agreement to be effective as of the date first set forth above.

      

      

      	 	
              COMPANY:

            
	 	 
	 	
              SC HEALTH CORPORATION

            
	 	 
	 	
              By:

            	 
	 	 	
              Name:

            
	 	 	
              Title:

            
	 	 	 
	 	
              PURCHASER:

            
	 	 
	 	
              SC HEALTH HOLDINGS LIMITED

            
	 	 
	 	
              By:

            	 
	 	 	
              Name:

            
	 	 	
              Title:

            

      

      

      

      

      

      

      [Signature Page to Private Placement Warrants Purchase Agreement]Exhibit 10.6

    

    

    THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR
      ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

     

    

    PROMISSORY NOTE

    

    

    	
            Principal Amount: Up to $300,000

          	
            Dated as of January 7, 2019

          

    

    

    SC Health Corporation, a Cayman Islands exempted company and blank check company (the ‘‘Maker”), promises to pay to the order of SC Health Holdings Limited, a
      Cayman Islands exempted company, or its registered assigns or successors in interest (the “Payee”), or order, the principal sum of Three Hundred Thousand Dollars ($300,000) or such lesser amount as shall have
      been advanced by Payee to Maker and shall remain unpaid under this Note on the Maturity Date (as defined below) in lawful money of the United States of America, on the terms and conditions described below. All payments on this Note shall be made by
      check or wire transfer of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by written notice in accordance with the provisions of this Note.

    

    

    
      1.          Principal. The entire unpaid principal balance of this Note shall be payable on the earlier of: (i)
        December 31, 2019 or (ii) the date on which Maker consummates an initial public offering of its securities (such earlier date of (i) and (ii), the “Maturity Date”). The principal balance may be prepaid at any
        time. Under no circumstances shall any individual, including but not limited to any officer, director, employee or shareholder of the Maker, be obligated personally for any obligations or liabilities of the Maker hereunder.

      

    

    2.         Drawdown Requests. Maker and Payee agree that Maker may request, from time to time, up to Three Hundred Thousand Dollars ($300,000) in drawdowns
      under this Note to be used for costs and expenses related to Maker’s formation and the proposed initial public offering of its securities (the “IPO”). Principal of this Note may be drawn down from time to time
      prior to the Maturity Date upon written request from Maker to Payee (each, a “Drawdown Request”). Each Drawdown Request must state the amount to be drawn down, and must not be an amount less than Ten Thousand
      Dollars ($10,000), unless agreed upon in writing by Maker and Payee. Payee shall fund each Drawdown Request no later than three (3) business days after receipt of a Drawdown Request; provided, however, that the maximum amount of drawdowns outstanding
      under this Note at any time may not exceed Three Hundred Thousand Dollars ($300,000). No fees, payments or other amounts shall be due to Payee in connection with, or as a result of, any Drawdown Request by Maker.

    

    

    3.          Interest. No interest shall accrue on the unpaid principal balance of this Note.

    

    

    4.         Application of Payments. All payments shall be applied first to payment in full of any costs incurred in
      the collection of any sum due under this Note, including (without limitation) reasonable attorney’s fees, then to the payment in full of any late charges and finally to the reduction of the unpaid principal balance of this Note.

    

    

    5.          Events of Default. The following shall constitute an event of default (“Event of Default”):

    

    

    (a)          Failure to Make Required Payments. Failure by Maker to pay the principal amount due pursuant to this Note within five (5) business days of the date specified above.

    

    

    (b)        Voluntary Bankruptcy, Etc. The commencement by Maker of a voluntary case under any applicable bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the
      consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee, custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for
      the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become due, or the taking of corporate action by Maker in furtherance of any of the foregoing.

    

    

    (c)          Involuntary Bankruptcy, Etc. The entry of a decree or order for relief by a court having jurisdiction in the premises in respect of Maker in an involuntary case under any
      applicable bankruptcy, insolvency or other similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the winding-up or
      liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days.

    

    

    6.          Remedies.

    

    

    (a)         Upon the occurrence of an Event of Default specified in Section 5(a) hereof, Payee may, by written notice to Maker, declare this Note to be due immediately and payable, whereupon the
      unpaid principal amount of this Note, and all other amounts payable thereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived, anything contained
      herein or in the documents evidencing the same to the contrary notwithstanding.

    

    

    (b)         Upon the occurrence of an Event of Default specified in Sections 5(b) or 5(c), the unpaid principal balance of this Note, and all other sums payable with regard to this Note, shall
      automatically and immediately become due and payable, in all cases without any action on the part of Payee.

    

    

    7.         Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive presentment for payment, demand, notice of dishonor, protest,
      and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might accrue to Maker by virtue of any present or future laws exempting
      any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of execution, exemption from civil process, or extension of time for
      payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may be sold upon any such writ in whole or in part in any order desired by Payee.

    
      
        

    

    8.         Unconditional Liability. Maker hereby waives all notices in connection with the delivery, acceptance, performance, default, or enforcement of the
      payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any indulgence, extension of time, renewal, waiver or modification granted or
      consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other provisions of this Note, and agrees that additional makers, endorsers,
      guarantors, or sureties may become parties hereto without notice to Maker or affecting Maker’s liability hereunder.

    

    

    9.         Notices. All notices, statements or other documents which are required or contemplated by this Agreement shall be: (i) in writing and delivered
      personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission to the address designated in writing, (ii) by facsimile to the number most recently provided to such party or such other
      address or fax number as may be designated in writing by such party or (iii) by electronic mail, to the electronic mail address most recently provided to such party or such other electronic mail address as may be designated in writing by such party.
      Any notice or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one
      (l) business day after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

    

    

    10.        Construction. THIS NOTE SHALL BE CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT REGARD TO CONFLICT OF LAW
      PROVISIONS THEREOF.

    

    

    11.        Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be
      ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in
      any other jurisdiction.

    

    

    12.       Trust Waiver. Notwithstanding anything herein to the contrary, the Payee hereby waives any and all right, title, interest or claim of any kind (“Claim”) in or to any distribution of or from the trust account to be established in which the proceeds of the IPO conducted by the Maker (including the deferred underwriters discounts and commissions) and the
      proceeds of the sale of the warrants issued in a private placement to occur prior to the effectiveness of the IPO are to be deposited, as described in greater detail in the registration statement and prospectus to be filed with the Securities and
      Exchange Commission in connection with the IPO, and hereby agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the trust account for any reason whatsoever.

    

    

    13.        Amendment; Waiver. Any amendment hereto or waiver of any provision hereof may be made with, and only with, the written consent of the Maker and the
      Payee.

    

    

    14.       Assignment. No assignment or transfer of this Note or any rights or obligations hereunder may be made by any party hereto (by operation of law or
      otherwise) without the prior written consent of the other party hereto and any attempted assignment without the required consent shall be void.

    

    

    [Signature page follows]

    
      
        

    

    

    

    IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by the undersigned as of the day and year first above
      written.

    

    

    	 	
            SC HEALTH CORPORATION

          
	 	
            a Cayman Islands exempted company

          
	 	 	 	 
	 	
            By:

          	
            /s/ David Sin

          
	 	 	
            Name :

          	
             David Sin

          
	 	 	
            Title:

          	
            Director

          

    

    

     Accepted and agreed this 7 day of January, 2019

     

    

    	
            SC HEALTH HOLDINGS LIMITED

            

          	 
	
            a Cayman Islands exempted company

          	 
	 	 	 	 
	
            By:

          	
            /s/ David Sin

          	 
	 	
            Name :

          	
             David Sin

          	 
	 	
            Title:

          	
            Director

          	 

    

    

    [Signature Page to Promissory Note]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00297-of-00352.parquet"}]]